text
"['\nX. 대주주 등과의 거래내용\n1. 주주 이외의 이해관계자와의 거래\n(1) 당반기 및 전반기 중 회사와 매출 등 거래 또는 채권, 채무 잔액이 있는 특수관계자 현황은 다음과 같습니다.\n관 계\n회\xa0 \xa0\xa0 사\xa0 \xa0\xa0 명\n종속기업\n㈜유한화학, ㈜유한메디카, ㈜엠지, ㈜유한건강생활, 애드파마㈜, YUHAN ZBEKISTAN\n관계기업 및 공동기업\n유한킴벌리㈜, ㈜유칼릭스, ㈜유한크로락스, ㈜한국얀센, ㈜이뮨온시아, ㈜씨.앤.씨,㈜워랜텍, ㈜아임뉴런바이오사이언스, ㈜지아이이노베이션, ㈜휴이노, 아말로이드솔루션㈜, ㈜지아이바이옴, ㈜메디오젠, ㈜에이프릴바이오, ㈜테라베스트, ㈜엔솔바이오사이언스\n기타특수관계자\n㈜리드팜, ㈜내츄럴엔도텍\n(2) 당반기 및 전반기 중 특수관계자와의 거래 내역은 다음과 같습니다.\n- 당반기\n\xa0(단위:천원)\n특수관계자의 명칭\n제상품매출\n임대, 용역수익\n기타(잡이익등)\n배당금수익\n매입등\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n(종속기업)\n\xa0㈜유한화학\xa0\n-\n1,800\n-\n-\n-\n-\n-\n-\n31,995,213\n69,335,219\n\xa0㈜유한메디카\n-\n1,455\n6,900\n13,800\n29,878\n29,878\n-\n-\n-\n-\n\xa0㈜엠지\n-\n-\n8,970\n17,940\n-\n-\n-\n-\n3,788,547\n5,336,150\n\xa0㈜유한건강생활\n-\n-\n261,653\n601,304\n5,865\n11,730\n-\n-\n2,967,573\n5,434,508\n\xa0애드파마㈜\n-\n-\n1,560\n31,516\n-\n5,000\n-\n-\n3,715,886\n6,042,659\n소 계\n-\n3,255\n279,083\n664,560\n35,743\n46,608\n-\n-\n42,467,219\n86,148,536\n(관계기업 및 공동기업)\n\xa0㈜유칼릭스\n-\n-\n-\n-\n-\n-\n-\n40,800\n15,792\n31,124\n\xa0㈜유한크로락스\n-\n-\n448,283\n788,765\n-\n-\n-\n2,747,500\n18,364,390\n33,421,680\n\xa0유한킴벌리㈜\n-\n-\n-\n-\n-\n-\n-\n19,500,000\n154,020\n705,780\n\xa0㈜한국얀센\n-\n-\n61,627\n181,962\n-\n-\n-\n-\n9,576,184\n18,799,247\n\xa0㈜이뮨온시아\n-\n-\n936\n1,872\n900\n1,800\n-\n-\n-\n-\n\xa0㈜씨.앤.씨\xa0\n-\n-\n-\n-\n-\n-\n-\n-\n1,628,787\n3,127,309\n\xa0㈜워랜텍\n-\n-\n-\n-\n26,782\n26,782\n-\n-\n228,811\n422,333\n\xa0㈜메디오젠\n-\n-\n-\n-\n-\n-\n-\n234,570\n256,462\n489,462\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0 소 계\n-\n-\n510,846\n972,599\n27,682\n28,582\n-\n22,522,870\n30,224,446\n56,996,935\n(기타특수관계자)\n\xa0㈜리드팜\n526,351\n1,269,249\n-\n-\n-\n-\n-\n-\n-\n3,482\n\xa0㈜내츄럴엔도텍\n-\n-\n-\n-\n-\n-\n2\n2\n31,864\n31,864\n소 계\n526,351\n1,269,249\n-\n-\n-\n-\n2\n2\n31,864\n35,346\n합 계\n526,351\n1,272,504\n789,929\n1,637,159\n63,425\n75,190\n2\n22,522,872\n72,723,529\n143,180,817\n- 전반기\n\xa0(단위:천원)\n특수관계자의 명칭\n제상품매출\n임대, 용역수익\n기타(잡이익등)\n배당금수익\n매입등\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n(종속기업)\n\xa0㈜유한화학\xa0\n-\n1,800\n-\n-\n-\n-\n-\n-\n29,249,649\n51,179,804\n\xa0㈜유한메디카\n-\n-\n6,900\n13,800\n51,818\n51,818\n-\n-\n-\n-\n\xa0㈜엠지\n-\n-\n-\n-\n-\n-\n-\n-\n272,211\n79,769\n\xa0㈜유한건강생활\n-\n-\n537,368\n803,893\n160,195\n160,195\n-\n-\n132,504\n214,196\n\xa0애드파마㈜\n-\n-\n34,164\n68,328\n-\n-\n-\n-\n6,370,132\n9,492,661\n소 계\n-\n1,800\n578,432\n886,021\n212,013\n212,013\n-\n-\n36,024,496\n60,966,430\n(관계기업 및 공동기업)\n\xa0㈜유칼릭스\n-\n-\n-\n-\n-\n-\n-\n40,800\n15,381\n30,708\n\xa0㈜유한크로락스\n-\n-\n408,403\n797,717\n-\n-\n-\n3,846,500\n17,000,419\n32,050,012\n\xa0유한킴벌리㈜\n-\n-\n-\n-\n-\n-\n-\n20,100,000\n1,203,617\n2,395,464\n\xa0㈜한국얀센\n-\n-\n120,841\n142,758\n-\n-\n-\n-\n9,176,882\n19,177,686\n\xa0㈜이뮨온시아\n-\n-\n936\n1,872\n900\n1,800\n-\n-\n500\n500\n\xa0㈜씨.앤.씨\xa0\n-\n-\n-\n-\n-\n-\n-\n-\n1,822,045\n3,743,614\n\xa0㈜아임뉴런바이오사이언스\n-\n-\n-\n-\n-\n-\n-\n-\n-\n1,200,000\n\xa0㈜워랜텍\n-\n-\n-\n-\n-\n-\n-\n-\n225,572\n529,387\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0 소 계\n-\n-\n530,180\n942,347\n900\n1,800\n-\n23,987,300\n29,444,416\n59,127,371\n(기타특수관계자)\n\xa0리드팜\xa0\n690,284\n1,280,887\n-\n-\n-\n-\n-\n-\n-\n834\n합 계\xa0\n690,284\n1,282,687\n1,108,612\n1,828,368\n212,913\n213,813\n-\n23,987,300\n65,468,912\n120,094,635\n(3)\xa0당반기말과\xa0전기말 현재 특수관계자와의 채권ㆍ채무는 다음과 같습니다.\n\xa0(단위:천원)\n특수관계자 명칭\n매출채권\n매입채무\n미수금 등 기타자산\n예수보증금\n당반기말\n전기말\n당반기말\n전기말\n당반기말\n전기말\n당반기말\n전기말\n(종속기업)\n\xa0㈜유한화학\xa0\n-\n-\n16,536,123\n8,737,830\n1,186,333\n311,702\n-\n-\n\xa0㈜유한메디카\n-\n-\n-\n-\n403,000\n403,000\n400,000\n400,000\n\xa0㈜엠지\n-\n-\n1,655,470\n2,085,516\n2,737,259\n2,737,259\n520,000\n-\n\xa0㈜유한건강생활\n91,412\n341,631\n2,475,553\n269,545\n2,151\n-\n528,000\n2,251,000\n\xa0YUHAN UZBEKISTAN\n171,516\n171,516\n-\n-\n-\n-\n-\n-\n\xa0애드파마㈜\n-\n-\n-\n-\n5,919,993\n3,380,019\n-\n-\n소 계\n262,928\n513,147\n20,667,146\n11,092,891\n10,248,736\n6,831,980\n1,448,000\n2,651,000\n(관계기업 및 공동기업)\n\xa0㈜유칼릭스\n-\n-\n277\n3,029\n-\n-\n-\n-\n\xa0㈜유한크로락스\n493,111\n429,311\n14,367,500\n12,021,324\n-\n-\n-\n-\n\xa0유한킴벌리㈜\n-\n20,093\n31,680\n864,395\n-\n-\n-\n-\n\xa0㈜한국얀센\n-\n-\n6,920,423\n4,661,158\n-\n-\n-\n-\n\xa0㈜이뮨온시아\n343\n-\n-\n-\n330\n-\n-\n-\n\xa0㈜씨.앤.씨\n-\n-\n1,016,689\n930,451\n-\n-\n-\n-\n\xa0㈜워랜텍\n-\n-\n171,181\n854,688\n-\n-\n-\n-\n\xa0㈜메디오젠\n-\n-\n275,503\n-\n-\n-\n-\n-\n소 계\n493,454\n449,404\n22,783,253\n19,335,045\n330\n-\n-\n-\n(기타특수관계자)\n\xa0㈜리드팜\n464,364\n507,836\n-\n-\n-\n-\n-\n-\n합 계\n1,220,746\n1,470,387\n43,450,399\n30,427,936\n10,249,066\n6,831,980\n1,448,000\n2,651,000\n(4) 당반기 및 전반기 중 특수관계자와의 자금거래 내역은 다음과 같습니다.\n(단위: 천원)\n특수관계 구분\n회사명\n당반기\n전반기\n대여\n회수\n출자\n대여\n회수\n출자\n종속기업\nYUHAN UZBEKISTAN\n-\n-\n226,360\n-\n-\n-\n㈜유한건강생활\n-\n-\n5,438,142\n-\n-\n-\nYUHAN USA CORPORATION\n-\n-\n1,666,200\n-\n-\n-\n관계기업 및 공동기업\n㈜지아이이노베이션\n-\n-\n9,999,990\n-\n-\n㈜휴이노\n-\n-\n-\n-\n-\n5,000,164\n아말로이드솔루션㈜\n-\n-\n-\n-\n-\n5,000,015\n㈜지아이바이옴\n-\n-\n-\n-\n-\n5,000,005\n㈜메디오젠\n-\n-\n-\n-\n-\n22,999,997\n㈜에이프릴바이오\n-\n-\n10,000,066\n-\n-\n-\n㈜아임뉴런바이오사이언스\n-\n-\n2,000,004\n-\n-\n-\n㈜테라베스트\n-\n-\n2,999,988\n-\n-\n-\n(5) 당반기말 현재 회사가 특수관계자에게 제공한 지급보증 및 담보 내역은 다음과 같습니다.\r\n(단위: 천원)\n특수관계자의 명칭\n보증 등의 내용\n금융기관\n보증 금액\n(종속기업)\n㈜유한건강생활\n운전자금대출\n국민은행\n5,500,000\n㈜유한건강생활\n일반대출\n신한은행\n3,600,000\n합\xa0 계\n9,100,000\n(6) 회사는 등기이사 및 회사 기업활동의 계획, 운영 및 통제에 대한 중요한 권한과 책임을 가진 등기 임원을 주요 경영진으로 판단하고 있으며, 당반기 및 전반기 중 주요 경영진에 대한 보상금액은 다음과 같습니다.\n(단위:천원)\n구\xa0 분\n당반기\n전반기\n3개월\n누적\n3개월\n누적\n단기종업원급여\n616,394\n2,111,953\n655,778\n1,720,112\n퇴직급여\n122,024\n244,048\n121,929\n243,858\n합 계\n738,418\n2,356,001\n777,707\n1,963,970\n']"
